Pharmacological Treatment of Bladder Stent Symptoms

Overview

Journal Bladder (San Franc)

Date 2024 Dec 6

PMID 39640188

Authors

John C P Piedad

Mazen Allam

Wasim Mahmalji

Affiliations

Soon will be listed here.

Abstract

Background: Ureteric stenting is a ubiquitous procedure, but it is associated with symptoms that affect psychological well-being and quality of life. While many factors are linked to worse symptomatology, some innovative modifications to the stent's structure, as well as treatments, have been studied to reduce their clinical impact. Pharmacotherapy is a well-evaluated treatment modality derived from the treatment of lower urinary tract symptoms not related to stents.

Objective: This review focuses on these pharmacological treatments. Several drug classes have been trialed to treat stent-related symptoms. Most of these studies investigated adrenoceptor modulators (both alpha-blockers and beta-3 agonists), muscarinic receptor antagonists, phosphodiesterase-5 inhibitors, as well as novel pharmacological modalities. Most trials and subsequent meta-analyses support treatment over placebo and controls, and some drugs are better at treating certain symptom domains, such as phosphodiesterase-5 inhibitors working on sexual issues. Furthermore, a combination therapy with alpha-blockers and muscarinic receptor antagonists appears to be superior to monotherapy with either of them. Treatments are also well tolerated.

Conclusion: However, initiating pharmacotherapy should be part of a shared decision-making approach that balances the severity of symptoms and the duration the stents will remain against potential side effects.

References

Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M . Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2014; 39(6):832-40. DOI: 10.1590/S1677-5538.IBJU.2013.06.09. View

Maldonado-Avila M, Garduno-Arteaga L, Jungfermann-Guzman R, Manzanilla-Garcia H, Rosas-Nava E, Procuna-Hernandez N . Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol. 2016; 42(3):487-93. PMC: 4920565. DOI: 10.1590/S1677-5538.IBJU.2015.0186. View

Dellis A, Papatsoris A, Keeley Jr F, Bamias A, Deliveliotis C, Skolarikos A . Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study. J Endourol. 2016; 31(1):100-109. DOI: 10.1089/end.2016.0663. View

Gangkak G, Teli R, Yadav S, Tomar V, Priyadarshi S, Aggarwal S . A single oral dose of Silodosin and Diclofenac sodium is effective in reducing pain after ureteric stent removal: a prospective, randomized, double blind placebo-controlled study. Springerplus. 2016; 5:23. PMC: 4705058. DOI: 10.1186/s40064-015-1662-7. View

Boeykens M, Keller E, Bosio A, Wiseman O, Contreras P, Ventimiglia E . Impact of Ureteral Stent Material on Stent-related Symptoms: A Systematic Review of the Literature. Eur Urol Open Sci. 2022; 45:108-117. PMC: 9587365. DOI: 10.1016/j.euros.2022.09.005. View

Nazim S, Ather M . Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol. 2012; 26(9):1237-41. DOI: 10.1089/end.2012.0036. View

Gao Y, Liang H, Liu L, Gurioli A, Wu W . Comparison of Alpha-Blockers and Antimuscarinics in Improving Ureteral Stent-Related Symptoms: A Meta-Analysis. Urol J. 2018; 16(3):307-311. DOI: 10.22037/uj.v0i0.4142. View

Lamb A, Vowler S, Johnston R, Dunn N, Wiseman O . Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int. 2011; 108(11):1894-902. DOI: 10.1111/j.1464-410X.2011.10170.x. View

He F, Man L, Li G, Liu N . Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison. Drug Des Devel Ther. 2016; 10:1783-93. PMC: 4887076. DOI: 10.2147/DDDT.S103195. View

10.

Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P . Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011; 186(3):928-34. DOI: 10.1016/j.juro.2011.04.061. View

11.

Shalaby E, Ahmed A, Maarouf A, Yahia I, Ali M, Ghobish A . Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol. 2013; 2013:752382. PMC: 3819880. DOI: 10.1155/2013/752382. View

12.

Van Besien J, Keller E, Somani B, Pietropaolo A, Claessens M, Merckx L . Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis. Eur Urol Focus. 2021; 8(4):1031-1041. DOI: 10.1016/j.euf.2021.10.002. View

13.

Falahatkar S, Beigzadeh M, Mokhtari G, Esmaeili S, Kazemnezhad E, Amin A . The effects of pregabalin, solifenacin and their combination therapy on ureteral double-J stent-related symptoms: A randomized controlled clinical trial. Int Braz J Urol. 2021; 47(3):596-609. PMC: 7993956. DOI: 10.1590/S1677-5538.IBJU.2020.0848. View

14.

Zhang K, Yan W, Li H, Chen J, Wang Q, Chai Y . Comparison of Mirabegron plus Tamsulosin and Tamsulosin Monotherapy for the Treatment of Ureteral Stent-Related Symptoms: A Prospective Randomized Study. Urol Int. 2022; 106(12):1226-1232. DOI: 10.1159/000526607. View

15.

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis I . Is there a role for alpha1-blockers in treating double-J stent-related symptoms?. Urology. 2006; 67(1):35-9. DOI: 10.1016/j.urology.2005.07.038. View

16.

Lee Y, Huang K, Yang H, Chang H, Chen J, Yang T . Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013; 41(3):247-52. DOI: 10.1007/s00240-013-0554-y. View

17.

Michel M, Vrydag W . Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006; 147 Suppl 2:S88-119. PMC: 1751487. DOI: 10.1038/sj.bjp.0706619. View

18.

Zhang L, Li J, Pan M, Han W, Liu S, Xiao Y . Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol. 2016; 42(4):727-33. PMC: 5006768. DOI: 10.1590/S1677-5538.IBJU.2015.0570. View

19.

Jian Z, Chen Y, Liu Q, Liao B, Yang T, Li H . Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis. World J Urol. 2018; 37(2):289-297. DOI: 10.1007/s00345-018-2404-6. View

20.

Park J, Yoo C, Han D, Shin D . A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol. 2015; 33(11):1833-40. DOI: 10.1007/s00345-015-1544-1. View